PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...

Miami researchers discover process to sustainably produce psilocybin - a drug candidate that could help treat depression

Andrew Jones at Miami University and his team of students may have developed a research first...


Researchers suspect that psilocybin — the psychedelic compound that puts the “magic” in magic mushrooms...


Dr. Jones is one of AIChE's 35 Under 35

The American Institute of Chemical Engineers (AIChE) has selected its latest group of engineers for their 35 Under 35 Award, and Dr. J...

PsyBio Therapeutics Announces Retention of Market Maker

PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic...

PsyBio Therapeutics Virtually Closes the Market

Evan Levine, Chief Executive Officer, PsyBio Therapeutics Corp. ("PsyBio" or "the Company") (TSXV: PSYB) and his team joined Dani Lipkin, Director, Global Business Development


About Us:

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.

Investment Deck:

© 2020 by PSYBIO